Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Monogram gets HIV test boost on Pfizer's news

This article was originally published in Clinica

Executive Summary

Monogram Biosciences has moved closer to marketing its HIV test for predicting response to a new type of drug being developed by Pfizer, after the pharmaceutical was given a favourable recommendation for approval by US FDA advisors. The agency's antiviral drugs advisory committee voted unanimously (12-0) to recommend that the drug, maraviroc, be approved for use along with other antiretroviral agents for treatment-experienced adults infected with CCR5-tropic HIV-1. Although not bound by its advisors' recommendations, the FDA usually follows them.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT048226

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel